The Soliris Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The Soliris market has experienced significant expansion in recent years. The market size is projected to increase from $1,880.37 million in 2024 to $2,030.44 million in 2025. The compound annual growth rate (CAGR) is set at 8.0%.
The Soliris market is projected to expand to $3,734.88 million in 2029, with a compound annual growth rate (CAGR) of 7.7%.
Download Your Free Sample of the 2025 Soliris Market Report and Uncover Key Trends Now!The key drivers in the soliris market are:
• The increasing prevalence of rare blood disorders is fueling the growth of the Soliris market.
• Improved diagnostic techniques, greater awareness, and genetic and environmental factors are contributing to more diagnosed cases of blood disorders.
• Soliris' ability to reduce risks of severe complications in rare blood disorder patients is driving its market growth.
• Significant investments in research and development for rare diseases are propelling the Soliris market expansion.
The soliris market covered in this report is segmented –
1) By Type: Plasma Exchange, Plasma Infusion
2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The key trends in the soliris market are:
• Market consolidation through strategic partnerships is gaining traction.
• There is a growing preference for biologic therapies.
• Regulatory approvals for expanded indications are influencing market dynamics.
• The emergence of biosimilars and rising healthcare expenditure are key trends to watch.
Major players in the soliris market are:
• Pfizer
North America leads the global Soliris market as per the Global Market Report 2025.